Search Clinical Trials
Sponsor Condition of Interest |
---|
4D-710 in Adult Patients With Cystic Fibrosis
4D Molecular Therapeutics
Cystic Fibrosis Lung
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational
gene therapy in adults with CF who are ineligible for or unable to tolerate CFTR
modulator therapy. expand
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with CF who are ineligible for or unable to tolerate CFTR modulator therapy. Type: Interventional Start Date: Mar 2022 |
Combined Exercise Trial
University of Kansas Medical Center
Healthy Aging
The number of older Americans will double in the next 4 decades to nearly 90 million,
placing an unprecedented financial and resource burden on the health care system.
Exercise has clear and demonstrable physical benefits, but a more precise understanding
of how exercise supports cognitive function... expand
The number of older Americans will double in the next 4 decades to nearly 90 million, placing an unprecedented financial and resource burden on the health care system. Exercise has clear and demonstrable physical benefits, but a more precise understanding of how exercise supports cognitive function is essential. Demonstrating definitively that exercise as recommended by public health entities has benefits for cognition would have enormous public health implications, encourage the public to adapt more active lifestyles, and stimulate the development of effective exercise delivery programs. Type: Interventional Start Date: Oct 2021 |
Prospective Study of Pregnancy in Women With Cystic Fibrosis
Amalia Magaret
Pregnancy Related
Cystic Fibrosis
In this study, the investigators aim to evaluate changes in lung function in women with
cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure
to highly effective cystic fibrosis transmembrane conductance regulator (CFTR)
modulators. expand
In this study, the investigators aim to evaluate changes in lung function in women with cystic fibrosis (CF) during pregnancy and for 2 years after pregnancy based on exposure to highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Type: Observational Start Date: Sep 2021 |
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients...
University of British Columbia
Aortic Stenosis
Coronary Artery Disease
Coronary Stenosis
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant
coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty
about the benefits and the optimal timing of revascularization for such patients. There
is currently clinical equipoise... expand
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascularization of coronary artery lesions. All patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD. Type: Interventional Start Date: Dec 2020 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Hormone Receptor-Positive Breast Carcinoma
This phase III trial compares the effect of active symptom monitoring and patient
education to patient education alone in helping young women with stage I-III breast
cancer stay on their hormone therapy medicines. The patient education tool contains
interactive weblinks which provide patients with... expand
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines. Type: Interventional Start Date: Mar 2023 |
More and Less Social Comprehension
University of Kansas Medical Center
Autism Spectrum Disorder
The goal of this early Phase 1 clinical trial is to assess if the social content of a
story impacts autistic children's listening comprehension of stories. The main questions
this study aims to answer are:
- Does removing social content from a story improve listening comprehension in
autistic... expand
The goal of this early Phase 1 clinical trial is to assess if the social content of a story impacts autistic children's listening comprehension of stories. The main questions this study aims to answer are: - Does removing social content from a story improve listening comprehension in autistic children? - Does listening comprehension of more social versus less social stories differentially predict performance on a standardized reading comprehension measure? Participants will listen to more social and less social stories while viewing accompanying pictures and answer comprehension questions about the stories and complete a standardized assessment of reading comprehension. In addition, participants complete measures of their nonverbal cognition, hearing status, autism severity, language abilities, and social communication abilities to help characterize individual differences in participants. Type: Interventional Start Date: Jul 2023 |
Treatment of Complex Pilon Fractures
University of Kansas Medical Center
Pilon Fracture
This project intends to compare patient outcomes between patients undergoing ORIF
compared to PA, or ankle fusion, following an acute pilon fracture. Limited literature
comparing ORIF and ankle fusion as a primary procedure exists. Particularly, no present
literature exists examining the novel arthrodesis... expand
This project intends to compare patient outcomes between patients undergoing ORIF compared to PA, or ankle fusion, following an acute pilon fracture. Limited literature comparing ORIF and ankle fusion as a primary procedure exists. Particularly, no present literature exists examining the novel arthrodesis surgical technique utilized in this study in conjunction with Opal sensor gait analysis data. This study will serve as a pilot study and assess patient gait, degree of pain, functional outcome scores, development of post-traumatic arthritis and/or infection, need for secondary surgery, and return to work time. Type: Observational Start Date: Aug 2023 |
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics, Inc.
Multiple Myeloma
Myeloma
Myeloma Multiple
A Phase I study to evaluate the safety of a novel, orally available, selective, and
potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also
known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with
relapsed or refractory multiple myeloma (RRMM). expand
A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM). Type: Interventional Start Date: Feb 2023 |
Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices
University of Kansas Medical Center
Dementia
The research team will train primary care practitioners from Kansas City clinics to
enhance skills in cultural competence, dementia detection, treatment and referral to a
Health Navigator among Latinos 65 and older with dementia. The Health Navigator will
provide patient/caregiver dyads referred by... expand
The research team will train primary care practitioners from Kansas City clinics to enhance skills in cultural competence, dementia detection, treatment and referral to a Health Navigator among Latinos 65 and older with dementia. The Health Navigator will provide patient/caregiver dyads referred by Alianza Latina providers with care management, psychosocial support and links to relevant community resources. Outcomes include feasibility and acceptability of 1) PCP training and 2) patient and caregiver dementia care. Type: Interventional Start Date: May 2022 |
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
St. Louis University
Giant Cell Tumor of Bone
The purpose of the clinical study is to investigate whether the local delivery of
bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of
bone coming back to the same location. The hypothesis is that the local administration of
bisphosphonate will decrease the rate of... expand
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor. Type: Interventional Start Date: May 2018 |
Ultrasound Guided Radiofrequency Ablation of the Occipital Nerve
University of Kansas Medical Center
Nerve Pain
Study an ultrasound guided approach to radiofrequency ablation of the occipital nerve
that makes it possible to see the needle during treatment procedure. It is hoped this
will reduce the amount of pain after the standard of care procedure. expand
Study an ultrasound guided approach to radiofrequency ablation of the occipital nerve that makes it possible to see the needle during treatment procedure. It is hoped this will reduce the amount of pain after the standard of care procedure. Type: Interventional Start Date: Jul 2022 |
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Polycythemia Vera
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV expand
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV Type: Interventional Start Date: Oct 2022 |
Assessment of CCM in HF With Higher Ejection Fraction
Impulse Dynamics
Heart Failure
Heart Failure With Preserved Ejection Fraction
Heart Failure With Mid Range Ejection Fraction
Heart Failure With Moderately Reduced Ejection Fraction
Diastolic Heart Failure
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac
Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and
≤60%. expand
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%. Type: Interventional Start Date: Feb 2022 |
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
McMaster University
Prostate Cancer
Cardiovascular Disease
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer.
RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying
cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer. expand
RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer. RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer. Type: Interventional Start Date: Oct 2015 |
Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study
University of Kansas Medical Center
Colon Adenocarcinoma
This trial evaluates how inhalational anesthesia (drawn in through the lungs) and total
intravenous anesthesia (TIVA) (through a needle in a vein in the arm) change the body's
ability to recover from surgery or whether they impact the immune system immediately
after surgery in patients with colon... expand
This trial evaluates how inhalational anesthesia (drawn in through the lungs) and total intravenous anesthesia (TIVA) (through a needle in a vein in the arm) change the body's ability to recover from surgery or whether they impact the immune system immediately after surgery in patients with colon cancer. It is unknown whether these types of anesthesia change recovery from surgery or change the chances cancer comes back following surgery. This study may help researchers learn how different types of anesthesia affect recovery from colon cancer surgery. Type: Interventional Start Date: May 2023 |
Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function...
University of Kansas Medical Center
Atrophy
The proposed project will evaluate the musculoskeletal outcomes of quadriceps and
hamstring muscle size and function following orthopedic knee surgery involving anterior
cruciate ligament (ACL) repair or reconstruction. Currently, the research team
collaborates with a team of orthopedic specialists... expand
The proposed project will evaluate the musculoskeletal outcomes of quadriceps and hamstring muscle size and function following orthopedic knee surgery involving anterior cruciate ligament (ACL) repair or reconstruction. Currently, the research team collaborates with a team of orthopedic specialists at the University of Kansas Health System and monitor muscle size post-knee repair and follow the standard of care (SOC) practices of the licensed physical therapists (PT). The proposed project will include a randomized clinical trial to observe the muscular outcomes following the current SOC plus supplementation of calcium-β-hydroxy-β-methylbutyrate (caHMB) or placebo. CaHMB has been shown to improve rates of muscle protein synthesis while suppressing muscle protein breakdown in healthy adults. The use of caHMB has also provided evidence of muscular protection from atrophy during prolonged bed rest. This evidence supports the utility in clinically injured athletes that are subjected to disuse atrophy from the inability to bear weight or participate in typical daily physical activity. Additionally, matched for activity-related knee injuries, female athletes are more susceptible to incurring a significant injury due to a variety of genetic, hormonal, biological, anatomical, and biomechanical predispositions. Therefore, the proposed study will recruit approximately 30 females over the age of 18 that have sustained an injury to the ACL and will plan to undergo reconstructive knee surgery involving the ACL. Subjects will be monitored and measured prior to their surgical date (T0), at 2-weeks post operative (T1), and every 6-weeks until they are cleared to return to sport (T2-TRTS). Participants will be randomly assigned 1:1 in a double-blind manner to either an experimental (EXPHMB) or placebo (CONPLA) group. Doses will be provided to the participants in coded containers and will complete their dosing and a record log of intake for the duration of their rehabilitation. Three 3-day food, exercise, and health record logs will be collected to monitor nutritional intake, activity, and menstrual patterns at T0, T3, and TRTS. Participant's assessments will include body composition analysis via bioelectrical impedance analysis for total and segmental muscle and fat mass, skeletal muscle mass, and body fat percent. We will collect ultrasound images of the quadriceps and hamstrings of the operative-involved limb (OPIL) and non-operative limb (NOPL) limbs for muscle cross-sectional area (mCSA), thickness (mT), subcutaneous fat thickness (TFAT), and corrected echo intensity (EICOR) at all time points. Strength and functional assessments will occur upon entrance to the study (T0), and after loaded exercise is indicated by the practitioner (T3-TRTS) to the tolerance of the athlete. These assessments include maximal voluntary isometric contractions (MVIC) for leg extension and leg curl, standing balance tests, single-leg and double-leg jump assessment, and drop landing deviation, all on dual force plates. Data will be analyzed using multiple three-way analyses of variance [surgical leg (OPIL vs. NOPL) x treatment (EXPHMB vs. CONPLA) x time (T0 vs. T1 vs. T2 vs. T3 vs. T4 vs. T5 vs. TRTS) for the dependent variables. Significance is established at p≤0.05 and follow-up ANOVAS, T-tests, and post-hoc analyses will be conducted when significance is present. The evidence from this study will support the practitioners and coaches' abilities to maximize recovery and training outcomes, respectively, in previously injured female athletes. Type: Interventional Start Date: May 2023 |
Remote Monitoring and Virtual Collaborative Care For Hypertension Control to Prevent Cognitive Decline...
University of Kansas Medical Center
Hypertension
This is a randomized, controlled, pragmatic trial designed as a "type I hybrid
effectiveness-implementation trial" that tests a hypertension program integrating a
virtual Collaborative Care Clinic (vCCC), home blood pressure monitoring, and telehealth
for lowering blood pressure (BP) in two health... expand
This is a randomized, controlled, pragmatic trial designed as a "type I hybrid effectiveness-implementation trial" that tests a hypertension program integrating a virtual Collaborative Care Clinic (vCCC), home blood pressure monitoring, and telehealth for lowering blood pressure (BP) in two health systems. Type: Interventional Start Date: Nov 2021 |
Smart Technology for Anorexia Nervosa Recovery
University of Kansas
Anorexia Nervosa
Anorexia nervosa (AN) has the highest mortality rate of any mental illness, with a
typical onset in adolescence. Although family-based interventions are efficacious for up
to 75 percent of adolescents with AN, approximately 30 percent will relapse after
recovery. There is a critical need to improve... expand
Anorexia nervosa (AN) has the highest mortality rate of any mental illness, with a typical onset in adolescence. Although family-based interventions are efficacious for up to 75 percent of adolescents with AN, approximately 30 percent will relapse after recovery. There is a critical need to improve treatments and prevent post-discharge relapse following acute treatment to improve outcomes for adolescents with AN. To address this critical need, the investigators developed an adaptive smart-phone based therapy support tool for teens with AN, called Smart Treatment for Anorexia Recovery (STAR). STAR is for adolescents between the ages of 13-21 who recently received acute treatment for AN (e.g., inpatient, residential, intensive outpatient, or day hospital) who are currently working with an outpatient therapist. STAR incorporates elements from the Unified Protocol and Acceptance and Commitment Therapy to target emotion avoidance, which the investigators hypothesize will lead to reductions in eating-disorder behaviors. The investigators will compare STAR to Present-focused Anorexia Nervosa Coping Treatment (PACT), which focuses on current life stressors and problems. The investigators' hypothesis is that STAR will improve outpatient treatment response and reduce relapse in adolescents discharged from intensive treatment for AN. The investigators will evaluate their hypotheses in two conditions: 1) STAR app and 2) PACT app. In both conditions, participants must be working with an individual outpatient therapist. Type: Interventional Start Date: May 2023 |
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous...
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for... expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C...
University of Kansas Medical Center
Cancer, Appendiceal
ColoRectal Cancer
The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using
mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and
mortality will measured using the Comprehensive Complication Index (CCI) score, Common
terminology criteria for adverse events... expand
The purpose of this trial is to compare the morbidity and mortality of CRS-HIPEC using mitomycin-C versus melphalan for colorectal peritoneal carcinomatosis. Morbidity and mortality will measured using the Comprehensive Complication Index (CCI) score, Common terminology criteria for adverse events (CTCAE version 4.03), and the Clavien-Dindo Classification. Type: Interventional Start Date: Jul 2017 |
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
AveXis, Inc.
Spinal Muscular Atrophy (SMA)
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in
the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN
protein levels and a selective dysfunction of motor neurons. SMA is an autosomal
recessive, early childhood disease with an... expand
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. Until recently, the mainstay of treatment for these patients was supportive medical care. However, advances in medical treatment focusing on gene replacement, gene enhancement, motor neuron protection and muscle enhancement is likely to change the management and prognosis of these patients in the future. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options. Type: Observational [Patient Registry] Start Date: Sep 2018 |
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
Impact Therapeutics, Inc.
Advanced Solid Tumors
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid
Tumors expand
A Phase 1 Dose Escalation and Expansion Study of IMP7068 Monotherapy in Advanced Solid Tumors Type: Interventional Start Date: Feb 2021 |
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Bio-Path Holdings, Inc.
Acute Myeloid Leukemia (AML)
The primary objectives of this study are to assess: (1) whether the combination of BP1001
plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR],
Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with
partial hematologic recovery [CRh], than... expand
The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission [CR], Complete Remission with incomplete hematologic recovery [CRi], Complete Remission with partial hematologic recovery [CRh], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML. Type: Interventional Start Date: May 2016 |
Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant...
University of Kansas Medical Center
Pancreas Cancer
Researchers want to discover if the new drug "TG01" will work with participants' bodies
to help their immune system attack any cancer cells that might still be in the blood
stream after surgery for pancreatic cancer.
The researchers will also investigate whether or not "TG01" combined with the other... expand
Researchers want to discover if the new drug "TG01" will work with participants' bodies to help their immune system attack any cancer cells that might still be in the blood stream after surgery for pancreatic cancer. The researchers will also investigate whether or not "TG01" combined with the other study drug, "Balstilimab", will show even greater efficacy. TG01 and Balstilimab are both experimental treatments and are not approved by the US Food and Drug Administration (FDA) as treatment in the United States, or elsewhere, for pancreatic cancer or any other type of cancer. Balstilimab has been studied in other cancers and has shown signs of efficacy. Another drug will be used in this study called "QS-21". It is not intended to treat any disease but is used in this study to improve the action of the study drug TG01. QS-21 has been approved by the US Food and Drug Administration (FDA) to be mixed with a vaccine used to prevent shingles. It has not been approved to be mixed with the study drug, TG01. Participants will undergo eligibility screening, weekly visits during treatment when receiving the study drug or study drug combination, two safety follow-up visits, at about 30 and 90 days after the last dose of study treatment, and long term follow up for about 12 months after the last dose of study treatment. Type: Interventional Start Date: Dec 2022 |
Clinical Outcomes and Healthcare Economics of SOLTIVE Compared to Ho:YAG Laser in Urolithiasis
University of Kansas Medical Center
Kidney Stone
To compare intraoperative as well as postoperative outcomes of SOLTIVE Thulium laser
compared to Ho:YAG laser for the treatment of urolithiasis.
The hypothesis is that utilizing the SOLTIVE Thulium laser for the treatment of
urolithiasis will result in a more efficient procedure, with comparable... expand
To compare intraoperative as well as postoperative outcomes of SOLTIVE Thulium laser compared to Ho:YAG laser for the treatment of urolithiasis. The hypothesis is that utilizing the SOLTIVE Thulium laser for the treatment of urolithiasis will result in a more efficient procedure, with comparable stone free rate to that of Holmium laser and subjective improvement in physician satisfaction. Type: Interventional Start Date: Sep 2022 |
- Previous
- Next